23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
27 oct. 2022 06h45 HE
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe to Report FY2023 Second Quarter Financial Results
24 oct. 2022 16h05 HE
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe to Present at Upcoming Investor Conferences
12 oct. 2022 16h10 HE
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
05 oct. 2022 08h21 HE
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
Daniel Chu Joins 23andMe as Chief Product Officer
19 sept. 2022 06h45 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today appointed Daniel Chu as Chief Product...
23andMe Reports FY2023 First Quarter Financial Results
08 août 2022 16h05 HE
|
23andMe Holding Co.
First quarter revenue grew 9% to $64.5 millionConsumer revenue grew 17% year over year due to the addition of telehealth revenueOn track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO,...
23andMe to Report FY2023 First Quarter Financial Results
25 juil. 2022 16h05 HE
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report...
23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results
26 mai 2022 16h05 HE
|
23andMe Holding Co.
Achieved FY2022 financial guidanceFourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectivelyNew genomic health services...
23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
12 mai 2022 16h10 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
15 mars 2022 06h45 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company with a mission to help people access,...